AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
- Conditions
- Symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF)
- Interventions
- Drug: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)Drug: Placebo to match CK-4021586
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 60
- Registration Number
- NCT06793371
- Locations
- πΊπΈ
The Linder Center for Research & Education at the Christ Hospital, Cincinnati, Ohio, United States
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
- Conditions
- Heart FailureHeart Failure With Reduced Ejection Fraction
- Interventions
- Drug: Omecamtiv Mecarbil (OM)Drug: Placebo
- First Posted Date
- 2024-12-16
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 1800
- Registration Number
- NCT06736574
- Locations
- πΊπΈ
Montefiore Medical Center (Moses Campus), Bronx, New York, United States
πΊπΈAdvanced Cardiovascular, LLC, Alexander City, Alabama, United States
πΊπΈSan Diego Cardiac Center, San Diego, California, United States
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
- Conditions
- PediatricSymptomatic Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 40
- Registration Number
- NCT06412666
- Locations
- πΊπΈ
Children's Hospital Los Angeles, Los Angeles, California, United States
πΊπΈUniversity of California, Los Angeles (UCLA), Los Angeles, California, United States
πΊπΈChildren's Hospital Colorado, Aurora, Colorado, United States
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
- Conditions
- Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 500
- Registration Number
- NCT06081894
- Locations
- π¦π·
Hospital Italiano de Buenos Aires Juan Domingo Peron, Buenos Aires, Argentina
π¦πΊFiona Stanley Hospital, AHF Unit, Murdoch, Australia
π§π·Instituto D'Or de Pesquisa e Ensino/Cardio Pulmonar da Bahia SA, Ondina, Salvador, Brazil
Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 44
- Registration Number
- NCT05924815
- Locations
- πΊπΈ
Celerion, Inc 2420, Tempe, Arizona, United States
A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: Placebo for CK-4021586
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 102
- Registration Number
- NCT05877053
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 170
- Registration Number
- NCT05767346
- Locations
- π©πͺ
Universitaetsklinikum Essen, Essen, Germany
π©πͺUniversitaetsklinikum Jena, Jena, Germany
π©πͺCharite-Universitatsmedizin Berlin - Campus Virchow Klinikum, Berlin, Germany
A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: Placebo for CK-3828136
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 57
- Registration Number
- NCT05662215
- Locations
- πΊπΈ
Labcorp Clinical Research Unit Inc., Dallas, Texas, United States
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 71
- Registration Number
- NCT05442775
- Locations
- πΊπΈ
University of California Irvine - ALS & Neuromuscular Center, Orange, California, United States
πΊπΈMayo Clinic Jacksonville, Jacksonville, Florida, United States
πΊπΈMichigan Medicine, Ann Arbor, Michigan, United States
Aficamten vs Placebo in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy (SEQUOIA-HCM)
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- Drug: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)Drug: Placebo to match aficamten
- First Posted Date
- 2022-01-11
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 282
- Registration Number
- NCT05186818
- Locations
- πΊπΈ
Cedars-Sinai Medical Center - Smidt Heart Institute Clinic, Los Angeles, California, United States
πΊπΈMedStar Medical Group Cardiology at Union Memorial, Baltimore, Maryland, United States
πΊπΈMedstar Franklin Square Medical Center, Baltimore, Maryland, United States